Inventage Lab Accelerates Building of Gene Therapy CDMO Ecosystem

InventiGELAB, a company specializing in microsphere long-acting injectables and lipid nanoparticle (LNP) research and development (R&D) manufacturing platforms, has begun actively establishing an LNP gene therapy contract development and manufacturing organization (CDMO) ecosystem by signing consecutive memorandums of understanding (MOUs) with gene therapy companies.

[Photo by Inventage Lab]

InventiGELAB recently announced on the 30th that it signed an MOU for strategic cooperation in the messenger ribonucleic acid (mRNA)-LNP therapeutic field with RNA Gene. RNA Gene is a startup company possessing capabilities in designing and optimizing genetic materials, which correspond to the active pharmaceutical ingredient (API) in gene therapy, R&D scale mRNA synthesis, and mRNA vaccine development, and has also undertaken COVID-19 vaccine development projects.

The collaboration structure between the two companies involves RNA Gene optimizing mRNA therapeutics tailored to disease characteristics and verifying the efficacy of candidate substances, while InventiGELAB handles LNP formulation optimization, LNP process optimization and scale-up, nonclinical and clinical sample production, and commercial manufacturing. As part of their strategic cooperation, they will jointly develop new mRNA-LNP therapeutics targeting rare indications. Based on mRNA therapeutics discovered and optimized by RNA Gene, InventiGELAB will proceed with formulation optimization, scale-up, and clinical development aiming for joint commercialization.

InventiGELAB also signed an MOU for strategic cooperation with MediciBio, a gene delivery technology and gene therapy development company. MediciBio holds proprietary patents for newly developed biodegradable ionizable lipids necessary for independent LNP commercialization. The newly developed ionizable lipids by MediciBio are evaluated to enhance gene delivery efficiency and, unlike existing ionizable lipids, reduce the immunogenicity of the delivery vehicle, enabling repeated administration and possessing characteristics suitable for cancer vaccine development, a major future field of LNP pharmaceuticals.

InventiGELAB expects to actively recommend the features and therapeutic advantages of MediciBio’s newly developed ionizable lipids to LNP therapeutic clients and to maximize the success potential of LNP therapeutics by actively adopting MediciBio’s ionizable lipids in the LNP formulation services performed by InventiGELAB. MediciBio will also provide its clients with InventiGELAB’s expertise in LNP formulation optimization, scale-up, and good manufacturing practice (GMP) manufacturing, cooperating to enhance the development stability of LNP therapeutics.

Possessing its proprietary LNP manufacturing system, ‘IVL-GeneFluidic,’ InventiGELAB signed a CDMO joint commercialization contract for LNP production with U-BioLogics in May, and with the recent MOU, it is realizing an LNP gene therapy value chain that maximizes synergy among companies from initial business feasibility review of LNP gene therapy development to candidate substance development, LNP formulation process finalization, and GMP production.

Kim Juhee, CEO of InventiGELAB, stated, “Currently, CDMO supply specialized in LNP gene therapeutics is absolutely insufficient in the market. InventiGELAB and its partners aim to conduct CDMO business in compliance with domestic and advanced country standards and will actively pursue business linkages by specialized fields to provide a comprehensive LNP gene therapy development platform service covering the entire process.”

This content was produced with the assistance of AI translation services.